KLRA — Kailera Therapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.08 | ||
| Price to Tang. Book | 4.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.52% | ||
| Return on Equity | -36.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kailera Therapeutics Inc is a United States-based company. The Company is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions. Its pipeline consists of clinical- and preclinical-stage programs with injectable peptides, oral peptides, and an oral small molecule.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- January 1st, 1970
- Incorporated
- May 8th, 2024
- Public Since
- April 17th, 2026
- No. of Shareholders
- 26
- No. of Employees
- 145
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 123,677,939
- Address
- 180 Third Ave, 4th Floor, WALTHAM, 02451
- Web
- https://www.kailera.com
- Phone
- +1 5084409475
- Auditors
- Ernst & Young LLP
Similar to KLRA
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals,
NASDAQ Global Select Market
Arcutis Biotherapeutics
NASDAQ Global Select Market
FAQ
As of Today at 12:31 UTC, shares in Kailera Therapeutics are trading at $21.04. This share price information is delayed by 15 minutes.
Shares in Kailera Therapeutics last closed at $21.04 and the price had moved by over the past 365 days. In terms of relative price strength the Kailera Therapeutics share price has matched the S&P500 Index by over the past year.
There is no consensus recommendation for this security.
Find out moreKailera Therapeutics does not currently pay a dividend.
Kailera Therapeutics does not currently pay a dividend.
Kailera Therapeutics does not currently pay a dividend.
To buy shares in Kailera Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $21.04, shares in Kailera Therapeutics had a market capitalisation of $2.60bn.
Here are the trading details for Kailera Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KLRA
Based on an overall assessment of its quality, value and momentum Kailera Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kailera Therapeutics. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $21.04, shares in Kailera Therapeutics were trading -11.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kailera Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Kailera Therapeutics' directors